ReviewPharmaceutics2021
Phthalocyanine and Its Formulations: A Promising Photosensitizer for Cervical Cancer Phototherapy.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Photodynamic effect of carbon dots and aluminum chloride phthalocyanine against skin cancer: modulation by an autophagy inducer.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Dual Anticancer and Antibacterial Applications of Active Particle Aggregates Containing Metal Phthalocyanines in Dark.International journal of molecular sciences · 2026Article
- Beyond chemotherapy: the evolving role of photodynamic therapy in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2026Review
- Multimodal phototherapy for Glioblastoma: from mechanistic action to synergistic delivery and therapeutic strategies.Journal of nanobiotechnology · 2026Review
- Co-encapsulation in Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as an Emerging Therapeutic Strategy.Molecular diagnosis & therapy · 2026Review
- The Role of MALDI-TOF Mass Spectrometry in Photodynamic Therapy: From Photosensitizer Design to Clinical Applications.Current issues in molecular biology · 2025Review
- Ulvan Microneedles Loaded with Photosensitizer 5-aminolevulinic Acid Inhibits Human Cervical Cancer HeLa CellsAnti-cancer agents in medicinal chemistry · 2025Article
- Cytotoxic Effects of Combinative ZnPcSInternational journal of molecular sciences · 2023Article
- Liposomes loaded with dual clinical photosensitizers for enhanced photodynamic therapy of cervical cancer.RSC advances · 2023Article
- (Nano)platforms in bladder cancer therapy: Challenges and opportunities.Bioengineering & translational medicine · 2023Review
- Low-Dose Near-Infrared Light-Activated Mitochondria-Targeting Photosensitizers for PDT Cancer Therapy.International journal of molecular sciences · 2022Article
- Delivery of Molecules Using Nanoscale Systems for Cancer Treatment and/or Diagnosis.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Cervical cancer is one of the most common causes of cancer-related deaths in women worldwide. Despite advances in current therapies, women with advanced or recurrent disease present poor prognosis. Photodynamic therapy (PDT) has emerged as an effective therapeutic alternative to treat oncological diseases such as cervical cancer. Phthalocyanines (Pcs) are considered good photosensitizers (PS) for PDT, although most of them present high levels of aggregation and are lipophilic. Despite many investigations and encouraging results, Pcs have not been approved as PS for PDT of invasive cervical cancer yet. This review presents an overview on the pathophysiology of cervical cancer and summarizes the most recent developments on the physicochemical properties of Pcs and biological results obtained both in vitro in tumor-bearing mice and in clinical tests reported in the last five years. Current evidence indicates that Pcs have potential as pharmaceutical agents for anti-cervical cancer therapy. The authors firmly believe that Pc-based formulations could emerge as a privileged scaffold for the establishment of lead compounds for PDT against different types of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.